Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe
by
, , , , , , , add
Show full author list
Winson Y. Cheung
1,*, 
Adam Lee
2,
Helena Bote de Cabo
3,
Kathrin Burdenski
4,
Petros Christopoulos
5,
Bárbara Pinto-Correia
6,
Simon Deshayes
7,
Nicolas Girard
8,
Pooja Hindocha
9,
Áine Madden
9,
Marta Mella
10,
Joana Moreira
6,
Silvia Rizzi
11,
Delvys Rodríguez Abreu
12,
Marta Soares
13,
Joseph Thomas
9,
Maria Han
14,
Christophe Y. Calvet
15,
Gabrielle Emanuel
16,†,
Mrudula B. Glassberg
17,
Hazel Jacobs
18,
Caroline Rault
19,
Yong Yuan
20 and
Christos Chouaid
21add
Show full author list
1
Oncology Outcomes, University of Calgary, Calgary, AB T2N 1N4, Canada
2
Health Economics & Outcomes Research, Oncology, Bristol Myers Squibb, Uxbridge UB8 1DH, UK
3
Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
4
University Cancer Center Frankfurt (UCT), 60590 Frankfurt am Main, Germany
5
Thoraxklinik at Heidelberg University Hospital and Translational Lung Research Center Member of the German Center for Lung Research, 69126 Heidelberg, Germany
6
IQVIA Ltd., Porto Salvo, 2740-266 Oeiras, Portugal
7
Center Hospitalier Universitaire de Caen, 14000 Caen, France
8
Institut du Thorax Curie-Montsouris, Institut Curie, 75248 Paris, France
9
IQVIA Ltd., London W2 1AF, UK
10
IQVIA Ltd., 20124 Milan, Italy
11
IQVIA Ltd., 2200 Copenhagen, Denmark
12
Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain
13
Portuguese Oncology Institute of Porto (IPO-Porto), 4200-162 Porto, Portugal
14
Vivantes Klinikum in Friedrichshain, 10249 Berlin, Germany
15
Global Medical, Bristol Myers Squibb, Princeton, NJ 08540, USA
16
Real World Data Analytics, Bristol Myers Squibb, Uxbridge UB8 1DH, UK
17
Health Economics & Outcomes Research, Bristol Myers Squibb, Madison, NJ 07940, USA
18
Syneos Health, Farnborough GU14 7BF, UK
19
Data Gnosis, 35000 Rennes, France
20
Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08540, USA
21
Centre Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun, 94000 Créteil, France
*
Author to whom correspondence should be addressed.
†
Current address: Centre for Observational Research, Amgen, Uxbridge UB8 1DH, UK.
Curr. Oncol. 2026, 33(3), 152; https://doi.org/10.3390/curroncol33030152
Submission received: 17 December 2025
/
Revised: 16 February 2026
/
Accepted: 27 February 2026
/
Published: 6 March 2026
(This article belongs to the Section Thoracic Oncology)
Simple Summary
There is currently an insufficient amount of real-world information on treatments and outcomes among people with advanced-stage non-small cell lung cancer (NSCLC) who have mutations in the ROS1 gene, termed ROS1-positive advanced NSCLC. We used pooled data collected between 2009 and 2024 from clinical sites in Canada, France, Germany, Portugal, and Spain to assess patients with ROS1-positive advanced NSCLC with the aim of describing patient characteristics, treatment patterns, and survival. In this study, results from 103 patients with ROS1-positive advanced NSCLC who received systemic anticancer therapy indicated a tendency for longer survival using currently available treatment that specifically targets ROS1-positive disease than with non-targeted treatments, such as chemotherapy. However, the observed survival outcomes were less than optimal, highlighting the importance of more effective emerging treatments for patients with ROS1-positive advanced NSCLC.
Abstract
Real-world data on patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) remain scarce. In this descriptive observational retrospective cohort study, we describe characteristics, treatments, and real-world progression-free survival (rwPFS) and overall survival (OS) among patients with ROS1-positive advanced NSCLC (de novo or recurrent) using secondary data pooled from clinical sites in Canada, France, Germany, Portugal, and Spain as part of the Oncology Evidence Network. Site-specific patient inclusion periods occurred between 2009 and 2023, with follow-up to 2024, allowing ≥1 year of potential follow-up at each site. In total, 108 patients were included, with most (n = 105; 97.2%) having a de novo diagnosis of advanced NSCLC. 103 patients (95.4%) received ≥1 line of systemic anticancer therapy (SACT), of which 65 (63.1%) received first-line targeted therapy, mostly crizotinib monotherapy (n = 45) or crizotinib-based regimens (n = 10), with a median (95% CI) rwPFS and OS of 14.0 (8.3–19.8) and 47.9 (27.3–not estimable) months, respectively. Thirty-eight of the 103 SACT-treated patients (36.9%) received first-line non-targeted therapy, mostly platinum-based chemotherapy (n = 26); median (95% CI) rwPFS and OS were 9.0 (7.5–11.0) and 29.3 (17.7–65.7) months, respectively. Results from this study indicated a tendency for longer survival using currently available ROS1-targeted versus non-targeted therapy for patients with ROS1-positive advanced NSCLC. Nevertheless, survival outcomes were limited, highlighting the importance of more effective emerging treatments for ROS1-positive disease.
